Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients

Clinical Lymphoma and Myeloma

Volumn 7, Issue 5, 2007, Pages 354-360

  Case Jr , Delvyn C ^a   Desch, Christopher E ^b   Kalman, Leonard A ^c   Vongkovit, Piyapong ^d   Mena, Raul R ^e   Fridman, Moshe ^f   Allen, Barbara ^g  

^a Maine Center for Cancer Medicine and Blood Disorders   (United States)

^b Virginia Cancer Institute   (United States)

^c Oncology Hematology Group of South Florida   (United States)

^d Northwestern Carolina Oncology and Hematology   (United States)

^e East Valley Hematology and Oncology Medical Group   (United States)

^f AMF Consulting   (United States)

^g AMGEN INC   (United States)

Author keywords

Chemotherapy; Granulocyte colony stimulating factor; Neutropenia

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY SAMPLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION RISK; LEUKOPENIA; LUNG INFILTRATE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RESPIRATORY FAILURE; SEPSIS; SUICIDE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EID: 34248175922     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.012     Document Type: Article

References (19)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
2. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) 2004; 2004:221-236.
3. Genentech Inc. Rituxan® (rituximab) full prescribing information. Available from: http://www.gene.com/gene/products/information/oncology/rituxan/ insert.jsp. Accessed July 20, 2005.
4. Coififier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
5. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MInT) group. Lancet Oncol 2006; 7:379-391.
6. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002; 29(2 suppl 6):18-22.
7. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89:3974-3979.
8. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5:895-900.
9. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430-1436.
10. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-3127.
11. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-3585.
12. Morrison VA, Weller EA, Haberman TM, et al. Patterns of growth factor (gf) usage and febrile neutropenia (fn) among older patients (pts) with diffuse large B-cell lymphoma (dlbcl) treated with CHOP or R-CHOP: an Intergroup experience (CALGB 9793, ECOG-SWOG 4494. Blood 2004; 104:904a.
13. Bosserman LD, Henderson IC. Cancer in America, 2004. Community Oncology 2004; 1:30-35.
14. Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988; 24:533-538.
15. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8:963-977.
16. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22:4302-4311.
17. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients widi intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2:47-56.
18. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003; 39:2264-2272.
19. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe D'Etude des Lymphomes de L'Adulte. Leuk Lymphoma 1997; 25:289-300.